A detailed history of Affinity Asset Advisors, LLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 147,500 shares of SWTX stock, worth $5.38 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares
147,500
Previous 69,999 110.72%
Holding current value
$5.38 Million
Previous $2.64 Million 79.25%
% of portfolio
0.82%
Previous 0.36%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$32.04 - $42.76 $2.48 Million - $3.31 Million
77,501 Added 110.72%
147,500 $4.73 Million
Q2 2024

Aug 14, 2024

SELL
$36.06 - $47.62 $1.08 Million - $1.43 Million
-30,001 Reduced 30.0%
69,999 $2.64 Million
Q4 2023

Feb 13, 2024

BUY
$18.94 - $37.24 $1.11 Million - $2.18 Million
58,419 Added 140.49%
100,000 $3.65 Million
Q3 2023

Nov 14, 2023

SELL
$23.12 - $31.38 $2.04 Million - $2.77 Million
-88,419 Reduced 68.01%
41,581 $961,000
Q2 2023

Aug 14, 2023

BUY
$23.15 - $32.71 $3.01 Million - $4.25 Million
130,000 New
130,000 $3.41 Million
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $4.22 Million - $6.94 Million
175,000 New
175,000 $4.99 Million
Q2 2022

Aug 12, 2022

SELL
$18.36 - $60.07 $4.53 Million - $14.8 Million
-247,000 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$48.97 - $65.46 $2.52 Million - $3.37 Million
-51,545 Reduced 17.27%
247,000 $13.9 Million
Q4 2021

Feb 11, 2022

BUY
$53.3 - $75.84 $9.2 Million - $13.1 Million
172,532 Added 136.92%
298,545 $18.5 Million
Q3 2021

Nov 12, 2021

BUY
$62.66 - $88.26 $6.33 Million - $8.92 Million
101,013 Added 404.05%
126,013 $7.99 Million
Q2 2021

Aug 13, 2021

SELL
$67.45 - $85.63 $134,900 - $171,260
-2,000 Reduced 7.41%
25,000 $2.06 Million
Q1 2021

May 14, 2021

BUY
$65.1 - $93.59 $1.76 Million - $2.53 Million
27,000 New
27,000 $1.99 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.27B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.